Overview

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Open label, dose escalation to evaluate safety.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sirnaomics